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The serological crossreactivity between certain enteric bacteria and HLA-1327
(1, 2) and/or an associated structure (3, 4) on the cells of patients with HLA-
B27+ ankylosing spondylitis (1327+,AS+) has been documented by some groups
in three different populations (5-7), but its relevance to the pathogenesis ofAS
remains obscure . An extension of these studies by our group has shown that
HLA-1327+ lymphocytes from normal individuals (1327+,AS-), which are not
lysed by crossreactive antisera (i.e ., antisera that specifically lyse B27+,AS' cells
[3, 4]), can be rendered susceptible to lysis after incubation in the culture filtrate
(containing modifying factor) of crossreactive bacteria (8, 9) . One possible
consequence of the modification by bacterial antigens of an HLA-B27-associated
structure is the production, by genetically susceptible individuals, of CTL that
would kill targets bearing HLA-1327 in association with certain bacterial antigens .
The destruction of target tissues (e.g ., synovium and other connective tissues) by
cytotoxic mechanisms might lead to an inflammatory reaction in the sacroiliac
and spinal joints, which is a characteristic lesion in AS . In support of this
possibility, we report that CTL, raised by stimulating the PBMC of an B27'},AS-
individual with thePBMC of an HLA-A-, -B-, -C-identical sibling suffering from
AS, will specifically lyse B27+,AS+ PBMC but not PBMC from HLA-1327+ or
1327-,AS- normal individuals or from HLA-1327- AS patients (1327-,AS+). More-
over, these disease-specific CTL will lyse B27+,AS- PBMC that have been
modified in vitro with culture filtrate from crossreactive bacteria . CTL of similar
specificity can also be raised by immunizing B27'',AS- cells with autologous cells
modified by crossreactive antigens in vitro .
Materials and Methods
Patients.
￿
All HLA-1127+ and HLA-1127- patients were suffering from classical anky-
losing spondylitis as defined by the New York criteria (10) . HLA-1127+ and HLA-1327-
healthy controls were members of staffand blood donors with no history ofjoint disease .
Bacterial Cultures .
￿
Klebsiella K43 BTS 1, a transformant of E. coli C600 that has
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acquired by transformation a gene encoding modifying factor (E. coli C600-pBBI ; J. S.
Sullivan, J. K. Prendergast, L. I . Upfold, and A. F. Geczy, manuscript submitted for
publication) and an E. coli from the bowel flora of an HLA-B27+ AS patient, were grown
in nutrient broth No. 2 or Luria broth (Oxoid, Basingstoke, England) with vigorous
aeration for 16-20 h at 37 °C. The culture filtrates were harvested by centrifugation at
5,000 g for 20 min, concentrated 20-fold with polyacrylate gel (11), and filtered through
a 0.2 um pore size membrane (Millipore, Bedford, MA).
Production of CTL to HLA-B27-associated Determinants.
￿
PBMC were obtained from
groups of HLA-B27+ (n = 12), and HLA-B27- (n = 4) patients with ankylosing spondylitis,
as well as from HLA-B27+ (n = 14) and HLA-B27- (n = 10) normal controls. The cells
were separated from heparinized blood by centrifugation in Lymphoprep (Nyegaard,
Oslo, Norway) for 25 min at 580 g, and washed in RPMI medium containing 10% human
AB serum (3). CTL were raised by incubating 10' mononuclear (fresh or frozen/thawed)
cells (responder cells) with 8-10 X 106 in vitro-modified or unmodified (e.g., B27+,AS+
PBMC) mitomycin-treated autologous or allogeneic mononuclear (stimulator) cells in 20
ml of RPMI medium and 20% human AB serum. The responder and stimulator cells
were incubated in 50-ml tissue culture flasks (Corning Glass Works, Corning, NY) at
37'C for 6-7 d in an atmosphere of 5% C02 in air. Mononuclear cells cultured for 6-7
d in the same medium without any stimulant were used as targets.
For the production of CTL to in vitro-modified HLA-B27, mononuclear cells (10'
B27+,AS- in 1 .9 ml of RPMI medium containing 20% human AB serum) were incubated
with 20-fold concentrated culture filtrate (0.1 ml) for 12-16 h at 37° C. The culture
filtrates were obtained from one of the crossreactive organisms, including Klebsiella K43
BTS 1, an E. coli from the bowel flora of a B27+,AS+ patient (Fig. 1 A), as well as an E.
coli transformant that had acquired a plasmid bearing a gene(s) encoding modifying factor
(E. coli C600-pBBI). After modification with culture filtrate, the PBMC were treated with
mitomycin C (Sigma Chemical Co., St. Louis, MO; 40 jug per 8-10 X 106 cells) for 30 min
at 37°C, washed twice with RPMI medium and 20% human AB serum, and used as
stimulator cells. When required as targets, they were incubated for 5-6 d in medium
alone and then modified for 12-16 h before use.
For the production of CTL to the putative disease-associated determinant, B27+,AS-
PBMC (8-10 X 106) were incubated with mitomycin-treated B27+,AS+ PBMC (8-10 X
106) from an HLA-A-, -B-, and -C-identical AS-affected sibling. After a 6-7-d incubation,
the CTL assay was run for 5-6 h at 37°C in round-bottomed 96-well plates using 10'
5 'Cr-labeled target cells (0.1 ml) and effector cells (0 .1 ml) at various E/T ratios (50, 10,
and 5:1). The amount of "Cr released into the supernatant was measured in a gamma
counter. Percent specific release was calculated as 100 X [(experimental release) -
(spontaneous release)]/[(total release) - (spontaneous release)]. Spontaneous release was
15-30% of the detergent control (total release).
CTL Competition Assay.
￿
Cold or unlabeled targets were treated the same as hot or "Cr-
labeled targets cells, except that they were not labeled with "Cr. Cold targets (0.1 ml)
were added to individual wells containing effector cells (0.05 ml) before the addition of
5'Cr-labeled target cells (0.1 ml). The cold target cells were added at various cold/hot cell
ratios from 5:1 to 50:1 .
Blocking of CTL Activity with Antibodies.
￿
Alloantisera (anti-HLA-B27 and -B44), mAb
(HLA-ABC M1, monomorphic anti-class I, 1 mg/ml; lot 418202, A.M.D ., Artarmon,
New South Wales, Australia) or normal human AB serum were added to individual wells
of microtiter plates together with 10' target cells. After a 45-min incubation at 37° C,
effector cells were added and the cultures were incubated for an additional 5 h before
harvesting.
Results and Discussion
Previous studies from our group (4, 8) have documented the specific modifi-
cation of B27+,AS- lymphocytes by a factor (modifying factor) in the culture
filtrate of certain crossreactive bacteria. We wished to determine whether CTL934
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FIGURE 1 . CTL raised to: (a) autologous in vitro-modified B27',AS- PBMC, and (b) a
disease-associated determinant developed by sensitizing the PBMC of a B27-,AS- normal
individual (A2, -; B27, Bw62; Cwl, Cw3) with PBMC of an HLA-A-, -B-, and -C-identical
sibling suffering from AS. The target cells used in these studies were: B27*,AS- PBMC
modified with crossreactive culture filtrate (O), B27+,AS+ PBMC (EI), B27',AS- PBMC
(unmodified) (0), B27-,AS+ PBMC (A), B27-,AS' PBMC modified with crossreactive culture
filtrate (9), B27-,AS- PBMC (unmodified) (A).
could be raised to crossreactive determinants in the context of HLA-B27. The
culture filtrates with this modifying factor activity were obtained not only from
the previously characterised isolate Klebsiella K43 BTS 1, but also from a
crossreactive E. coli isolated from the bowel flora of an AS patient. This E. coli
might be of particular relevance to the pathogenesis of AS, since fecal isolates of
E. coli with crossreactive determinants have so far been recovered from all 52
patients with AS, but from only one of 50 B27-,AS- controls (12). The culture
filtrate of a transformant of E. coli C600 was also used to modify B27'',AS-
PBMC. This isolate of E. coli has acquired by transformation a gene(s) encoding
modifying factor (E. coli C600pBB1 ; J. S. Sullivan, J. K. Prendergast, L. 1.
Upfold, and A. F. Geczy, manuscript submitted for publication). As culture
filtrates of all crossreactive bacteria have similar modifying factor activity (4, 13)
we considered it reasonable to use these filtrates interchangeably .
Fig. 1A shows that CTL, raised to B27',AS- cells that had been modified in
vitro with culture filtrate of an E. coli from the bowel flora ofa B27'',AS+patient,
will kill not only B27',AS- cells treated with culture filtrate, but also B27+ cells
from AS patients. However, these CTL will not lyse the cells of B27- AS patients
or of unmodified B27+ normal controls . The cells of B27- normal controls that
have been modified with culture filtrate are also not lysed, suggesting that the
crossreactive determinants are seen only in association with HLA-B27.
As an extension to the studies on in vitro-modified B27',AS- PBMC, we
attempted to raise CTL to the putative disease-associated determinant by stim-
ulating cells from an HLA-B27+ normal individual with cells from an HLA-
identical sibling suffering from AS (the diagnosis of AS was based on the New
York criteria [10]) . The resultsin Fig. 1 B show that CTL to this disease-associated
structure will lyse B27+,AS+ PBMC well as in vitro-modified B27',AS- PBMC.
By contrast, the PBMC of B27-,AS patients and of B27+ and B27- normal
controls are not killed, indicating that these CTL recognize a hypothetical
disease-associated structure only in the context of HLA-B27.GECZY ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
935
80 r
°~ 60 A
m
m
U
d
G
N
20
a
5 10 20 50
Cold/Hot Target Ratio
FIGURE 2. Cold target inhibition studies of CTL directed against the disease-associated
determinant on B27',AS' PBMC. The E/T ratio was 25:1 and the unblocked activity is
indicatedby a star (*). Cold targets (0.1 ml)were added to wellscontaining effector cells(0.05
ml) before the addition of "Cr-labeled target cells (0.1 ml). The cold target cells were added
at various cold/hot cell ratios from 5:1 to 50:1 . The following cold target cells were tested:
B27',AS- PBMC modified with crossreactive culture filtrate (O), B27+,AS+ PBMC ([]),
B27',AS- PBMC (unmodified) (/), B27-,AS+ PBMC (A), B27-,AS- PBMC (unmodified) (A).
The CTL activity wasassayed as described in Materialsand Methods.
CTL to the B27-associated determinant on B27+,AS+ PBMC have so far been
raised in two families: in one family, the patient and the normal sibling were,
HLA-A2, -; 1327, Bw62 ; Cw1, Cw3 (see Fig. IB) and in the other family: HLA-
A2, Aw33; B27, Bw71 ; Cwt, Cw2 (results not shown) .
These CTL, like the crossreactive antibacterial sera (3, 4), recognize a similar
or an identical determinant on B27',AS+ cells and on in vitro-modified
1327+,AS- cells. It is likely, therefore, that CTL will prove to be useful typing
reagents for the detection of B27-associated determinants on the cells of patients
and their family members. To confirm the specificity of the CTL raised to
1327+,AS' PBMC, cold target inhibition studies were performed, and these results
are illustrated in Fig. 2. It is clear that only B27+,AS+ and modified B27+,AS-
PBMC are able to block CTL activity, while no blocking is seen in the presence
of cold targets from the three other categories of PBMC (i.e., B27-,AS+,
1327+,AS-, and B27-,AS-).
To demonstrate further the requirement for HLA-1327 in the 1327-associated
complex recognized by CTL, alloantisera and a monomorphic anti-class I serum
were used to block CTL activity. The data in Table I show that the CTL activity
of effector cells against the B27-associated determinant can be blocked when
modified B27+,AS- target cells are exposed to an monomorphic anti-class I
serum or to an antiserum to HLA-1327. In contrast, anti-1344, which is also
expressed on the target cell, failed to block CTL activity.
The observations reported here indicate that the PBMC of patients suffering
from ankylosing spondylitis carry an HLA-1327-associated determinant that can
be specifically recognized by CTL. These CTL, which have so far been tested
on 12 B27+, 4 B27- AS patients, and on 10 B27+ and 10 B27- normal controls,
are specific for modifying factor or the disease-associated determinant in associ-
ation with HLA-1327.
The specificity of the CTL documented in this report raises a number of
interesting possibilities with respect to the initiation of the disease in genetically936
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TABLE I
Ability ofAnti-HLA-B27 Serum to Block CTL Activity against a
B27-associated Determinant
Summary
Received forpublication 7 April 1986 and in revisedform 19June 1986
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Effector cells were produced by stimulating B27*, AS- PBMC with in vitro-
modified autologous PBMC; target cells were modified B27*, AS- PBMC (for
details see Materials and Methods).
* Final concentration ofserum or antibody in microtiter wells during CTL assay.
$ Percent inhibition = 100 x (1- specific release in presence ofantiserum)/(specific
release in presence of control serum).
susceptible individuals. It is tempting to suggest that CTL specific for modified
HLA-1127 might destroy target tissue bearing HLA-1127, in association with
certain factors derived from crossreactive bacteria, and thereby induce an inflam-
matory reaction . IF CTL or similar cytotoxic mechanisms play a role in the
pathogenesis of AS, then perhaps some connective tissues are better targets than
others possibly because they present to the effector cells a more recognizable or
compatible structure.
To our knowledge, this is the first demonstration of CTL to HLA-1127
modified by bacterial products, and we suggest that these CTL may represent a
plausible effector mechanism in the pathogenesis of AS.
Cytotoxic T lymphocytes, induced by stimulating the PBMC of an HLA-1127+
normal individual (1127+,AS-) with the PBMC of an HLA-identical sibling suf-
fering from ankylosing spondylitis (AS) (1127+,AS+), specifically lyse B27+,AS+
PBMC but not PBMC from HLA-27+ or B27-,AS- normal controls, or from
HLA-1127- AS patients (1127-,AS{'). CTL of similar specificity can also be raised
by immunizing in vitro B27-,AS- cells with autologous cells modified by cross-
reactive bacterial antigens. These results suggest that CTL can recognize certain
bacterial antigens in association with HLA-1127 and that this interaction may
lead to an inflammatory episode during the initial stages of the disease.
1. Avakian, H., J.Welsh, A. Ebringer,andC. C. Entwistle. 1980. Ankylosingspondylitis,
HLA-1127 and Klebsiella. II . Cross-reactivity studies with human tissue typing sera.
Br. J. Exp. Pathol. 61 :92.
2. Van Bohemen, C. G., F. C. Grumet, and H. C. Zanen. 1984 . Identification of HLA-
B27M I and-M2 cross-reactive antigens in Klebsiella, Shigella andYersinia. Immunology.
52 :607 .
3. Geczy, A. F., K. Alexander, H. V. Bashir,J. P. Edmonds, L. Upfold, andJ. Sullivan.
Percent specific
Inhibition (%)$
Serum release
Exp.1 Exp.2 Exp.1 Exp.2
Human AB (1:5)* 65 58 - -
Anti-HLA-1127 (1 :5) 14 23 78 60
Anti-HLA-1144 (1 :5) 73 57 0 0
Anti-class I (monomorphic) (1 :50) 18 16 72 72GECZY ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
93 7
1983 . HLA-1327, Klebsiella, and ankylosing spondylitis: biological and chemical
studies. Immunol. Rev. 70:23.
4 . Prendergast, J. K., J. S. Sullivan, A. F. Geczy, L. I . Upfold, J. P. Edmonds, H. V.
Bashir, and E. Reiss-Levy. 1983. Possible role ofenteric organisms in the pathogenesis
of ankylosing spondylitis and other seronegative arthropathies. Infect. Immun. 41 :935.
5 . Archer, J. R., M. M. Stubbs, H. L. F. Currey, and A. F. Geczy. 1985. An antiserum
to Klebsiella K43 BTS 1 specifically lyses the lymphocytes of HLA-1327-positive
patients from a London population. Lancet 1:344.
6 . Van Rood, J. J., A. Van Leeuwen, P. Ivanyi, A. Cats, B. S. Breur-Vriesendorp, A. J.
Dekker-Saeys, A. Kijlstra, and E. Van Kregten. 1985. Blind confirmation of Geczy
factor in ankylosing spondylitis. Lancet. ii:943 .
7 . McGuigan, L. E., A. F. Geczy, J. K. Prendergast, J. P. Edmonds, H. H. Hart, and H.
V. Bashir. 1986. HLA-B27-associated cross-reactive marker on the cells of New
Zealand patients with ankylosing spondylitis. Ann. Rheum. Dis. 45:144.
8. Geczy, A. F., K. Alexander, H. V. Bashir, and J. Edmonds. 1980. A factor(s) in
Klebsiella culture filtrates specifically modifies an HLA-1327-associated cell-surface
component. Nature (Lond.). 283:782 .
9. Sullivan, J., L. Upfold, A. F. Geczy, H. V. Bashir, and J. P. Edmonds. 1982.
Immunochemical characterization ofKlebsiella antigens which specifically modify an
HLA-B27-associated cell-surface component. Hum. Immunol. 5:295 .
10. Bennett, P. H., and T. A. Burch . 1967. New York symposium on population studies
in the rheumatic diseases: New diagnostic criteria. Bull. Rheum. Dis. 17:453.
11 . Vartak, H. G., M. V. Rele, M. Rao, and V. V . Deshpande. 1983. A method for
concentrating dilute solutions of macromolecules. Anal. Biochem. 133 :260.
12. McGuigan, L. E., J. K. Prendergast, A. F. Geczy, J. P. Edmonds, and H. V. Bashir.
1986 . The significance ofnon-pathogenic "cross-reactive" bowel flora in patients with
ankylosing spondylitis. Ann. Rheum. Dis. In press.
13. Prendergast, J. K., L. E. McGuigan, A. F. Geczy, T. S. L. Wong, and J. P. Edmonds.
1984 . Persistence of HLA-1327 cross-reactive bacteria in bowel flora of patients with
ankylosing spondylitis. Infect. Immun. 46:686.